As of Jul 02
| +0.25 / +0.11%|
The 20 analysts offering 12-month price forecasts for Valeant Pharmaceuticals have a median target of 255.00, with a high estimate of 300.00 and a low estimate of 207.00. The median estimate represents a +11.60% increase from the last price of 228.49.
The current consensus among 21 polled investment analysts is to Buy stock in Valeant Pharmaceuticals. This rating has held steady since June, when it was unchanged from a Move your mouse over past
months for detail
Move your mouse over a quarter or year to see how estimates have changed over time.